CORONA CORONA Remedies Q4 FY26 results (Jan–Mar 2026) and concall
CORONA Remedies Limited delivered a robust performance in Q4 and FY26, significantly outpacing industry growth with strong revenue and PAT expansion. The company's strategic focus on chronic and semi-chronic therapies, coupled with successful acquisitions and new product launches, positions it for continued growth, despite a temporary dip in Q4 margins attributed to growth investments.
You’re reading a preview. Opening the full call uses 1 concall credit.
Sign in to use your monthly call allowance.
What they filed
Q4 FY26: revenue up 20.1%, net profit up 45.2% against the same quarter last year.
| Line item | Q2 FY25 | Q3 FY25 | Q4 FY25 | Q1 FY26 | Q2 FY26 | Q3 FY26 | Q4 FY26 |
|---|---|---|---|---|---|---|---|
| Revenue | 314 | 298 | 294 | 347 | 361 +15% | 342 +15% | 353 +20% |
| EBITDA | 67 | 69 | 54 | 70 | 78 +16% | 83 +20% | 62 +15% |
| Net profit | 43 | 45 | 31 | 46 | 52 +21% | 41 −9% | 45 +45% |
How to read this
₹ crore, as filed. The percentage beside a figure is the change against the same quarter a year earlier — never the quarter before, which would make every seasonal business look like it collapses and booms each year.
Inve summary of a publicly available earnings call transcript; see how call summaries are prepared. Not investment advice.
